154 related articles for article (PubMed ID: 35852878)
1. Metformin and breast cancer: an opportunity for pharmacogenetics.
Cuyàs E; Martin-Castillo B; Menendez JA
Aging (Albany NY); 2022 Jul; 14(14):5612-5613. PubMed ID: 35852878
[No Abstract] [Full Text] [Related]
2. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer.
He X; Esteva FJ; Ensor J; Hortobagyi GN; Lee MH; Yeung SC
Ann Oncol; 2012 Jul; 23(7):1771-80. PubMed ID: 22112968
[TBL] [Abstract][Full Text] [Related]
3. Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer.
Guppy A; Jamal-Hanjani M; Pickering L
Future Oncol; 2011 Jun; 7(6):727-36. PubMed ID: 21675836
[TBL] [Abstract][Full Text] [Related]
4. Metformin pharmacogenomics: biomarkers to mechanisms.
Wang L; Weinshilboum R
Diabetes; 2014 Aug; 63(8):2609-10. PubMed ID: 25060891
[No Abstract] [Full Text] [Related]
5. Cracking open window of opportunity trials.
Kalinsky K; Hershman DL
J Clin Oncol; 2012 Jul; 30(21):2573-5. PubMed ID: 22565006
[No Abstract] [Full Text] [Related]
6. Is Metformin effective in Breast Cancer (BC) patients without Type 2 Diabetes (T2D)?
Siddiqui T; ; Doultani PR
J Pak Med Assoc; 2023 Apr; 73(4):953. PubMed ID: 37052031
[No Abstract] [Full Text] [Related]
7. Metformin effects on malignant cells and healthy PBMC; the influence of metformin on the phenotype of breast cancer cells.
Damjanović A; Matić IZ; Ðorđić M; Ðurović MN; Nikolić S; Roki K; Milovanović Z; Antić-Stanković J; Džodić R; Damjanović S; Kanjer K; Abu Rabi Z; Juranić Z
Pathol Oncol Res; 2015 Jul; 21(3):605-12. PubMed ID: 25351941
[TBL] [Abstract][Full Text] [Related]
8. The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy.
Vazquez-Martin A; Oliveras-Ferraros C; del Barco S; Martin-Castillo B; Menendez JA
Ann Oncol; 2009 Mar; 20(3):592-5. PubMed ID: 19153119
[No Abstract] [Full Text] [Related]
9. [Genetic testing of constitutive sensitivity to metformin in cancer patients with and without diabetes].
Bershteĭn LM; Vasil'ev DA; Ievleva AG; Imianitov EN
Vopr Onkol; 2013; 59(6):714-20. PubMed ID: 24624779
[TBL] [Abstract][Full Text] [Related]
10. Diabetes and Metformin Association with Recurrence Score in a Large Oncotype Database of Breast Cancer Patients.
Tharakan S; Zimmerman B; Ru M; Blanter J; Cascetta K; Tiersten A
Oncology; 2020; 98(8):589-592. PubMed ID: 32182614
[TBL] [Abstract][Full Text] [Related]
11. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial.
Hadad S; Iwamoto T; Jordan L; Purdie C; Bray S; Baker L; Jellema G; Deharo S; Hardie DG; Pusztai L; Moulder-Thompson S; Dewar JA; Thompson AM
Breast Cancer Res Treat; 2011 Aug; 128(3):783-94. PubMed ID: 21655990
[TBL] [Abstract][Full Text] [Related]
12. Association of Metformin with Breast Cancer Incidence and Mortality in Patients with Type II Diabetes: A GRADE-Assessed Systematic Review and Meta-analysis.
Tang GH; Satkunam M; Pond GR; Steinberg GR; Blandino G; Schünemann HJ; Muti P
Cancer Epidemiol Biomarkers Prev; 2018 Jun; 27(6):627-635. PubMed ID: 29618465
[No Abstract] [Full Text] [Related]
13. Metformin and Breast Cancer: Molecular Targets.
Faria J; Negalha G; Azevedo A; Martel F
J Mammary Gland Biol Neoplasia; 2019 Jun; 24(2):111-123. PubMed ID: 30903363
[TBL] [Abstract][Full Text] [Related]
14. Metformin: "Old warrior for a new battle".
Jain A
Indian J Cancer; 2010; 47(4):471-2. PubMed ID: 21131766
[No Abstract] [Full Text] [Related]
15. Metformin improves the outcomes in Chinese invasive breast cancer patients with type 2 diabetes mellitus.
Hui T; Shang C; Yang L; Wang M; Li R; Song Z
Sci Rep; 2021 May; 11(1):10034. PubMed ID: 33976288
[TBL] [Abstract][Full Text] [Related]
16. Potential and real 'antineoplastic' and metabolic effect of metformin in diabetic and nondiabetic postmenopausal females.
Berstein LM; Vasilyev DA; Iyevleva AG; Boyarkina MP; Poroshina TE; Khadzhimba AS; Imyanitov EN
Future Oncol; 2015; 11(5):759-70. PubMed ID: 25757680
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.
Yam C; Esteva FJ; Patel MM; Raghavendra AS; Ueno NT; Moulder SL; Hess KR; Shroff GS; Hodge S; Koenig KH; Chavez Mac Gregor M; Griner RL; Yeung SJ; Hortobagyi GN; Valero V
Invest New Drugs; 2019 Apr; 37(2):345-351. PubMed ID: 30610588
[TBL] [Abstract][Full Text] [Related]
18. Association between pancreatic cancer and metformin use in patients with type 2 diabetes.
Lai SW; Tsai CH; Lin CL; Liao KF
Postgrad Med J; 2019 May; 95(1123):291. PubMed ID: 30975725
[No Abstract] [Full Text] [Related]
19. Pharmacogenetics of oral antidiabetic therapy.
Ordelheide AM; Hrabě de Angelis M; Häring HU; Staiger H
Pharmacogenomics; 2018 Apr; 19(6):577-587. PubMed ID: 29580198
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents.
Goodwin PJ; Stambolic V; Lemieux J; Chen BE; Parulekar WR; Gelmon KA; Hershman DL; Hobday TJ; Ligibel JA; Mayer IA; Pritchard KI; Whelan TJ; Rastogi P; Shepherd LE
Breast Cancer Res Treat; 2011 Feb; 126(1):215-20. PubMed ID: 20976543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
